Selective Estrogen Receptor Modulators Market
Number of pages: 100 | Report Format: PDF | Published date: June 15, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
7.9% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Indication, Drug, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global selective estrogen receptor modulators market is expected to register a revenue CAGR of 7.9% from 2023 to 2031.
Selective Estrogen Receptor Modulators Market Fundamentals
Selective estrogen receptor modulators (SERMs) are drugs that interact with estrogen receptors in the body, exerting selective effects on different tissues. They are designed to bind to estrogen receptors in specific tissues while having different effects in other tissues. SERMs can act as estrogen agonists (mimicking the effects of estrogen) in some tissues and as estrogen antagonists (blocking the effects of estrogen) in others. The primary target of SERMs is the estrogen receptor, a protein found in various tissues throughout the body. Two subtypes of estrogen receptors are estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ). SERMs can selectively target these receptor subtypes, leading to distinct effects.
Selective Estrogen Receptor Modulators Market Dynamics
Hormone-related conditions such as breast cancer, osteoporosis, and postmenopausal symptoms are becoming increasingly prevalent. SERMs offer targeted treatment options for these conditions by modulating the effects of estrogen, making them a valuable therapeutic choice. For instance, according to the Centers for Disease Control and Prevention, every year, about 264,000 breast cancer patients are diagnosed in the U.S. SERMs have demonstrated benefits in managing osteoporosis, particularly in postmenopausal women. They can improve bone mineral density and reduce the risk of fractures. As the aging population grows and the prevalence of osteoporosis increases, the demand for SERMs as an effective treatment option is expected to rise and thus boost the global selective estrogen receptor modulators market. Furthermore, continuous advancements in drug development, including the design of novel SERMs with improved efficacy and safety profiles, are driving the market. Efforts to develop SERMs with tissue-specific effects and reduced side effects are expected to fuel the demand for these drugs further.
However, although SERMs benefit specific tissues, they can also have side effects. Common side effects include hot flashes, vaginal dryness, and an increased risk of blood clots. These safety concerns can affect patient compliance and limit the widespread use of SERMs. Moreover, the SERMs market may face competition from alternative treatments or therapies for the same indications; in the case of breast cancer treatment, other hormonal therapies, such as aromatase inhibitors, may be preferred over SERMs in certain patient populations. Additionally, side effects and safety concerns, competition from alternative treatments, and alternative treatment modalities are some of the restraints impeding the overall market growth.
Selective Estrogen Receptor Modulators Market Ecosystem
The global selective estrogen receptor modulators market is analyzed from three perspectives: indication, drug, and region.
Selective Estrogen Receptor Modulators Market by Indication
Based on the indication, the global selective estrogen receptor modulators market is segmented into osteoporosis, postmenopausal, breast cancer, fertility, and others.
The osteoporosis segment dominated the market with the top revenue share in 2022, owing to the rising prevalence of osteoporosis globally. For instance, according to the International Osteoporosis Foundation, it is estimated that 75 million people in Europe, the U.S., and Japan have osteoporosis. Osteoporosis is characterized by low bone mass and structural deterioration of bone tissue, leading to an increased risk of fractures. SERMs have effectively managed and prevented osteoporosis, particularly in postmenopausal women. Decreased estrogen levels primarily cause postmenopausal osteoporosis after menopause. Estrogen plays a crucial role in maintaining bone health, and the decline in estrogen leads to accelerated bone loss. SERMs act as estrogen agonists in bone tissue, helping to preserve bone mineral density and reduce the risk of fractures. These aspects contribute to the growth of the osteoporosis segment.
The postmenopausal segment also accounted for a major revenue share of the market in 2022. SERMs have been extensively studied and used in postmenopausal women for various indications, including the management of menopausal symptoms and the prevention and treatment of conditions like osteoporosis and breast cancer. Post-menopause refers to the stage in a woman's life after she has undergone menopause, which is marked by the cessation of menstrual cycles for at least 12 consecutive months. During menopause, there is a significant decline in estrogen levels, leading to various physiological changes and an increased risk of certain health conditions. SERMs offer targeted treatment options for these conditions by selectively modulating estrogen receptors in different tissues. These parameters contribute to the growth of the postmenopausal segment.
Selective Estrogen Receptor Modulators Market by Drug
Based on the drug, the global selective estrogen receptor modulators market is segmented into tamoxifen, raloxifene, lasofoxifene, ospemifene, clomiphene, and toremifene.
The tamoxifen segment accounted for a prominent share of the market in 2022. Tamoxifen is one of the most well-known and widely used SERMs, primarily indicated for the treatment and prevention of estrogen receptor-positive breast cancer. It has been extensively studied and prescribed for various stages of breast cancer, making it a cornerstone therapy in breast cancer management. Tamoxifen is primarily used in the treatment of estrogen receptor-positive breast cancer. It acts as an estrogen receptor antagonist in breast tissue, effectively blocking the effects of estrogen. By doing so, tamoxifen inhibits the growth of breast cancer cells and helps prevent disease recurrence. It is commonly prescribed as adjuvant therapy after surgery, radiation, or chemotherapy to reduce the risk of cancer recurrence. Tamoxifen is also used for breast cancer risk reduction in high-risk women. It has been shown to reduce the incidence of invasive breast cancer in both pre-and postmenopausal women at increased risk. This preventive use of tamoxifen is particularly beneficial for women with a family history of breast cancer or certain genetic mutations associated with increased breast cancer risk. These factors contribute to the growth of the tamoxifen segment.
The raloxifene segment also accounted for a significant share of the market. Raloxifene is a SERM that is primarily indicated for the prevention and treatment of postmenopausal osteoporosis. It has also been studied for its potential benefits in other areas, such as breast cancer risk reduction. Raloxifene is approved for the prevention and treatment of postmenopausal osteoporosis. It works as an estrogen agonist in bone tissue, helping preserve bone mineral density and reduce the risk of fractures. Osteoporosis is prevalent in postmenopausal women, and the demand for effective treatments like raloxifene is high. Raloxifene acts as an estrogen agonist in bone tissue, protecting against bone loss, while functioning as an estrogen antagonist in other tissues such as the breast and uterus. This selective tissue action is a key advantage, as it benefits bone health while minimizing the risk of certain estrogen-related adverse events, such as endometrial hyperplasia or cancer. These factors contribute to the growth of the raloxifene segment.
Selective Estrogen Receptor Modulators Market by Region
Geographically, the global selective estrogen receptor modulators market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the global selective estrogen receptor modulators market with the largest revenue share in 2022, attributed to major contributors to the pharmaceutical industry, well-established healthcare systems, and technologically improved healthcare IT. North America is a hub for pharmaceutical research and development. Many leading pharmaceutical companies and regional research institutions conduct studies and clinical trials related to SERMs. This fosters innovation, drives advancements in the field, and contributes to the market segment’s growth. Additionally, the region has a relatively high prevalence of conditions that are treated with SERMs, such as postmenopausal osteoporosis and breast cancer. The aging population, particularly postmenopausal women, contributes to the increased demand for effective therapies like SERMs.
Selective Estrogen Receptor Modulators Market Competitive Landscape
The prominent players operating in the global selective estrogen receptor modulators market are:
Selective Estrogen Receptor Modulators Market Strategic Developments
Selective estrogen receptor modulators (SERMs) are a class of drugs that interact with estrogen receptors in the body, exerting selective effects on different tissues.
The revenue CAGR of the selective estrogen receptor modulators market during the forecast period will be 7.9% from 2023 to 2031.
Some key companies operating in the global selective estrogen receptor modulators market arePfizer Inc., Astra Zeneca, Sanofi S.A., Mylan Pharmaceuticals, and Zydus Pharmaceuticals USA Inc.
Side effects, safety concerns, and competition from alternative treatments restrict the global market growth to its full potential.
The increasing prevalence of hormone-related conditions, increasing awareness and screening programs, and advancements in drug development are likely to drive market growth.
*Insights on financial performance are subject to the availability of information in the public domain
Recommended Reports